XML 23 R47.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements & Derivative Instruments - Additional Information (Detail) (USD $)
 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended
Dec. 31, 2012
Dec. 12, 2012
Sep. 30, 2012
Jun. 17, 2010
Jan. 31, 2011
Unidym, Inc. [Member]
Dec. 31, 2012
Unidym, Inc. [Member]
Sep. 30, 2012
Unidym, Inc. [Member]
Dec. 31, 2012
Ablaris Therapeutics, Inc. [Member]
Fair Value Measurements Disclosure [Line Items]                
Non cash consideration received in sale of interest in subsidiary, bonds         $ 2,500,000      
Bond convertible conversion price per share         $ 2.00      
Fair value of derivative relating to third party         26,310 0 10,645  
Loss from change in value of the derivative asset, net of the derivative liability 239,605              
Derivative asset 30,011   280,261     0    
Loss from change in fair value of the derivative asset           250,250    
Warrants issued to acquire Common Stock   912,543   329,649        
Warrants outstanding 322,150              
Non-cash gain (loss) from change in fair value of the derivative liability 274,451             9,428
Duration of exchange rights 7 years              
Exchange right convertible conversion ratio for first year               0.06
Exchange right convertible conversion ratio for second year               0.04
Exchange right convertible conversion ratio for third year               0.03
Exchange right convertible conversion ratio for fourth year               0.02
Exchange right convertible conversion ratio for fifth year and beyond               0.01
Number of exchange rights sold               675,000
Contingent consideration $ 173,621   $ 173,621